cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.kt7u5v
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Meganola mediofusca László, Ronkay & Witt, 2007",
 {
 "or" : [
 "Country is United States of America",
 "Country is United States",
 "Country is United States of America",
 "Country is Canada",
 "Continent is North America"
 ]
 }
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0131548-210914110416597/datasets/export for details.
DOI: 10.15468/dl.7ddtwj
title: Occurrence Download

description: A dataset containing 4470 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Hippocamelus bisulcus (Molina, 1782)"
 ]
}

 The dataset includes 4470 records from 23 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0056405-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.so2386
title: Occurrence Download

description: A dataset containing 3582 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Amazona finschi (P.L.Sclater, 1864)"
 ]
}

 The dataset includes 3582 records from 44 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0040295-160910150852091/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.54yta2
title: Occurrence Download

description: A dataset containing 17 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((34.75195 30.55957,30.74414 27.60645,32.64258 22.05176,41.85352 11.29394,46.84571 16.28613,38.90039 28.66113,34.75195 30.55957))",
 "TaxonKey is Porites lutea Milne Edwards & Haime, 1851"
 ]
}

 The dataset includes 17 records from 4 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0213166-200613084148143/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.kbrq00
title: Occurrence Download

description: A dataset containing 4337 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Pilea microphylla (L.) Liebm."
 ]
}

 The dataset includes 4337 records from 214 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0010536-180131172636756/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25934/pr00012267
title: A Double-blind, Placebo-controlled, Randomized Dose Ranging Trial to Determine the Safety and Efficacy of Three Dose Levels of EMA401 in Reducing 24-hour Average Pain Intensity Score in Patients With Post-herpetic Neuralgia

description: This study was designed to characterize dose response, and evaluate safety and efficacy of three different doses of EMA401 compared to placebo in patients with post-herpetic neuralgia (PHN).
DOI: 10.13130/rd_unimi/6np0bt/9veaga
title: Giugno_1894_Pagina_015.jpg

description: Bulletin of 1894/06/04
DOI: 10.13130/rd_unimi/nsvbhr/nxf46f
title: Giugno_1890_Pagina_057.jpg

description: Bulletin of 1890/06/15
DOI: 10.13130/rd_unimi/xu1sm0/tbwvnu
title: Giugno_1893_Pagina_032.jpg

description: Bulletin of 1893/06/08
DOI: 10.25574/03182
title: Chandra X-ray Observatory ObsId 03182

description: MERGER SHOCKS IN CLUSTERS OF GALAXIES
DOI: 10.25934/pr00012268
title: A Double-blind, Placebo-controlled, Randomized Trial to Determine the Safety and Efficacy of EMA401 in Reducing 24-hour Average Pain Intensity Score in Patients With Painful Diabetic Neuropathy (EMPADINE)

description: The purpose of this study is to evaluate safety and efficacy of EMA401 compared to placebo in patients with painful diabetic neuropathy (PDN).
DOI: 10.13130/rd_unimi/cbrkhv/zyf20f
title: Gennaio_1927_Pagina_047.jpg

description: Bulletin of 1927/01/12
DOI: 10.13130/rd_unimi/jvs9pt/ibnnac
title: Giugno_1892_Pagina_031.jpg

description: Bulletin of 1892/06/08
DOI: 10.25934/pr00012269
title: Letrozole in the Treatment of Severe and Recurrent Endometriosis

description: Endometriosis is a condition in which abnormal growth of tissue histologically resembling the lining of the uterus (endometrium) is present outside of the uterus. This study will investigate the effect of a daily dose of letrozole compared to GnRH is safe and in addition effective in reducing measurable endometriosis lesions and in reducing pain in patients with active endometriosis which were pretreated with GnRH analogs for 2 months.
DOI: 10.13130/rd_unimi/awv4gb/1cgzvw
title: Giugno_1896_Pagina_010.jpg

description: Bulletin of 1896/06/03
DOI: 10.13130/rd_unimi/gsbgp1/ngay9h
title: Giugno_1889_Pagina_073.jpg

description: Bulletin of 1889/06/19
DOI: 10.13130/rd_unimi/rjrjox/i1epov
title: Luglio_1895_Pagina_076.jpg

description: Bulletin of 1895/07/19
DOI: 10.13130/rd_unimi/v8alup/ranqjw
title: Giugno_1891_Pagina_054.jpg

description: Bulletin of 1891/06/14
DOI: 10.25934/pr00012270
title: A Dose Blinded Extension Study to the CBAF312A2201 Study to Evaluate Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

description: This study consisted of a two year dose blinded phase during which patients received one of five doses of siponimod (10, 2, 1.25, 0.5 or 0.25mg) following which patients were switched to open label treatment with siponimod 2mg for approximately a further 3 years. It will provide data on long term safety, tolerability and efficacy of siponimod in the RRMS patient population
DOI: 10.13130/rd_unimi/6np0bt/ucbrux
title: Giugno_1894_Pagina_016.jpg

description: Bulletin of 1894/06/04
DOI: 10.13130/rd_unimi/xu1sm0/1dxetg
title: Giugno_1893_Pagina_033.jpg

description: Bulletin of 1893/06/09
DOI: 10.25574/03183
title: Chandra X-ray Observatory ObsId 03183

description: DEEP X-RAY IMAGE OF A133
DOI: 10.25934/pr00012271
title: A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK 3475 in Patients With Advanced Renal Cell Carcinoma

description: This is an open-label, 2 part study of pazopanib and/or MK 3475 in treatment naïve subjects with advanced RCC. Part 1 consists of a Phase I dose escalation of pazopanib + MK 3475 followed by an expansion cohort to determine the maximum tolerated regimen and the recommended Phase II dose. Part 2 is a randomized 3-arm Phase II study to evaluate the clinical efficacy and safety of pazopanib + MK 3475 as compared to single-agent pazopanib and single-agent MK 3475. The objectives of this Phase I/II study are to test the safety and tolerability of pazopanib in combination with MK 3475, and study the clinical efficacy of pazopanib in combination with MK 3475 in subjects with advanced RCC as compared with single-agent pazopanib and single-agent MK 3475.Following the Urgent Safety Measure (USM) released on February 09, 2017, the phase II (Part 2) portion of this study will not commence.
DOI: 10.13130/rd_unimi/cbrkhv/wft9xd
title: Gennaio_1927_Pagina_048.jpg

description: Bulletin of 1927/01/12
DOI: 10.13130/rd_unimi/nsvbhr/ic7xfo
title: Giugno_1890_Pagina_058.jpg

description: Bulletin of 1890/06/15
DOI: 10.25934/pr00012272
title: A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney

description: To estimate the difference in efficacy and safety of bevacizumab and RAD001 compared to bevacizumab and interferon alfa-2a for first-line treatment of patients with metastatic carcinoma of the kidney.
DOI: 10.13130/rd_unimi/awv4gb/exuxmm
title: Giugno_1896_Pagina_011.jpg

description: Bulletin of 1896/06/03
DOI: 10.13130/rd_unimi/jvs9pt/notto4
title: Giugno_1892_Pagina_032.jpg

description: Bulletin of 1892/06/08
DOI: 10.13130/rd_unimi/rjrjox/fs2j99
title: Luglio_1895_Pagina_088.jpg

description: Bulletin of 1895/07/22
DOI: 10.13130/rd_unimi/v8alup/fqogrm
title: Giugno_1891_Pagina_055.jpg

description: Bulletin of 1891/06/14
DOI: 10.25934/pr00012273
title: An Open Label Study to Assess the Utility of Measuring Markers of Inflammation, to Detect Transition From Optimal to Sub-Optimal Inhaled Corticosteroid Therapy in Moderate-Severe Bronchial Asthma

description: The purpose of this study is to investigate/assess the treatment of moderate to severe asthmatics with inhaled corticosteroid.
DOI: 10.13130/rd_unimi/6np0bt/aa4ji4
title: Giugno_1894_Pagina_017.jpg

description: Bulletin of 1894/06/05
DOI: 10.13130/rd_unimi/gsbgp1/osuvqz
title: Giugno_1889_Pagina_074.jpg

description: Bulletin of 1889/06/19
DOI: 10.25574/03184
title: Chandra X-ray Observatory ObsId 03184

description: A DETAILED STUDY OF THE CLUSTER 1E 0657-56
DOI: 10.25934/pr00012274
title: An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients With Evidence of Persistent Leukemia by RQ-PCR.

description: The primary goal of this study was to determine the rate of confirmed best cumulative complete molecular response (CMR) within the first year of study therapy with imatinib or nilotinib. The study also explored the impact and significance of the achieved CMR on patient outcomes (progression free survival (PFS), event free survival (EFS) and overall survival (OS), characterized the kinetics of CMR achieved in both treatment arms and after the cross-over.
DOI: 10.13130/rd_unimi/cbrkhv/nvffit
title: Gennaio_1927_Pagina_049.jpg

description: Bulletin of 1927/01/13
DOI: 10.13130/rd_unimi/nsvbhr/5m2qro
title: Giugno_1890_Pagina_059.jpg

description: Bulletin of 1890/06/15
DOI: 10.13130/rd_unimi/xu1sm0/mj9nbn
title: Giugno_1893_Pagina_034.jpg

description: Bulletin of 1893/06/09
DOI: 10.25934/pr00012275
title: A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy

description: A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy
DOI: 10.13130/rd_unimi/awv4gb/m1vooj
title: Giugno_1896_Pagina_012.jpg

description: Bulletin of 1896/06/03
DOI: 10.13130/rd_unimi/rjrjox/2pd2kv
title: Luglio_1895_Pagina_089.jpg

description: Bulletin of 1895/07/23
DOI: 10.13130/rd_unimi/v8alup/ufpx6t
title: Giugno_1891_Pagina_056.jpg

description: Bulletin of 1891/06/14
DOI: 10.25934/pr00012276
title: A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44

description: The core study assessed the efficacy of a higher dose of rivastigmine 13.3 mg/24 h transdermally (15 cm\^2 patch) compared to a lower dose of the rivastigmine 4.6 mg/24 h transdermally (5 cm\^2 patch) in patients with Severe Dementia of the Alzheimer's Type in a 24-week study. The extension study obtained additional safety and efficacy data, as well as provided the higher dose rivastigmine patch to all patients who completed the core study for an additional 24 weeks.
DOI: 10.13130/rd_unimi/6np0bt/xhykyo
title: Giugno_1894_Pagina_018.jpg

description: Bulletin of 1894/06/05
DOI: 10.13130/rd_unimi/gsbgp1/wa01rp
title: Giugno_1889_Pagina_075.jpg

description: Bulletin of 1889/06/19
DOI: 10.13130/rd_unimi/jvs9pt/j0gosd
title: Giugno_1892_Pagina_033.jpg

description: Bulletin of 1892/06/09
DOI: 10.15468/dl.6yb4md
title: Occurrence Download

description: A dataset containing 8370 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Xenopus laevis",
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is one of (Fossil, Living Specimen)"
 ]
 }
 },
 {
 "or" : [
 "CoordinateUncertaintyInMeters is less than 10000",
 "CoordinateUncertaintyInMeters is null"
 ]
 }
 ]
}

 The dataset includes 8370 records from 83 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0054864-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25574/03185
title: Chandra X-ray Observatory ObsId 03185

description: A DETAILED STUDY OF THE CLUSTER A907
DOI: 10.25934/pr00012277
title: A 2-year Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Administered Either Annually at Randomization and 12 Months, or Administered at Randomization Only in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia

description: Osteoporosis prevention is important in patients with osteopenia (low bone density). This study will test the safety and efficacy of zoledronic acid in patients diagnosed with osteopenia.
DOI: 10.13130/rd_unimi/cbrkhv/0pmqxh
title: Gennaio_1927_Pagina_050.jpg

description: Bulletin of 1927/01/13
DOI: 10.13130/rd_unimi/nsvbhr/fcuwei
title: Giugno_1890_Pagina_060.jpg

description: Bulletin of 1890/06/15
DOI: 10.13130/rd_unimi/xu1sm0/6udtlb
title: Giugno_1893_Pagina_035.jpg

description: Bulletin of 1893/06/09
DOI: 10.25934/pr00012278
title: A Randomized Phase Lll Study of Imatinib Dose Optimization Compared With Nilotinib in Patients With Chronic Myelogenous Leukemia and Suboptimal Response to Standard-dose Imatinib

description: There is no available data on the clinical benefit of dose escalation for patients with suboptimal response to imatinib, and patients may still improve their response with continuation of therapy at the standard dose as shown in the IRIS trial after 5 years of follow-up. However, there is no data yet regarding the potential benefit of using nilotinib in the group of patients with suboptimal response. In this study, the efficacy of nilotinib 400mg BID will be compared to imatinib 600mg QD.
DOI: 10.25934/pr00012279
title: A Multi-center, Randomized, 12-week Treatment, Doubleblind Study to Assess the Efficacy and Safety of QMF149 (150/80 Microgram) Compared With MF Twisthaler® (200 Microgram) in Adult and Adolescent Patients With Asthma

description: The purpose of the trial was to evaluate efficacy and safety of QMF149 150/80 microgram o.d.delivered via Concept1 compared to MF 200 microgram o.d., delivered via Twisthaler® in terms of lung function and symptom control in poorly (ie inadequately) controlled asthma patients. This study was to assess contribution of LABA as an add-on therapy to low dose ICS monotherapy.
DOI: 10.13130/rd_unimi/awv4gb/diu8yn
title: Giugno_1896_Pagina_013.jpg

description: Bulletin of 1896/06/04
DOI: 10.13130/rd_unimi/rjrjox/gpfknw
title: Luglio_1895_Pagina_090.jpg

description: Bulletin of 1895/07/23
DOI: 10.25934/pr00012280
title: A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Patients With Asthma

description: The purpose of the trial is to evaluate the efficacy and safety of two different doses of QMF149 (QMF149 150/160 µg and QMF149 150/320 µg via Concept1) over two respective MF doses (MF 400 µg and MF 800 µg via Twisthaler® (total daily dose)) in poorly controlled asthmatic participants as determined by pulmonary function testing, and effects on asthma control
DOI: 10.13130/rd_unimi/6np0bt/q2c3or
title: Giugno_1894_Pagina_019.jpg

description: Bulletin of 1894/06/05
DOI: 10.13130/rd_unimi/gsbgp1/ivan3t
title: Giugno_1889_Pagina_076.jpg

description: Bulletin of 1889/06/19
DOI: 10.13130/rd_unimi/jvs9pt/rw0snu
title: Giugno_1892_Pagina_034.jpg

description: Bulletin of 1892/06/09
DOI: 10.13130/rd_unimi/v8alup/mmemdr
title: Giugno_1891_Pagina_057.jpg

description: Bulletin of 1891/06/15
DOI: 10.25574/03186
title: Chandra X-ray Observatory ObsId 03186

description: OLEGS OR FOSSIL GROUPS -- STUDYING EVOLVED GALAXY SYSTEMS
DOI: 10.25934/pr00012281
title: A 26 Week, Randomized, Active-controlled Safety Study of Double-blind Formoterol Fumarate in Free Combination With an Inhaled Corticosteroid Versus an Inhaled Corticosteroid in Adolescent and Adult Patients With Persistent Asthma.

description: The purpose of this study was to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, asthma related intubations, and asthma related deaths) in adolescents and adults (12 years of age and older) taking inhaled formoterol fumarate/fluticasone propionate combination was the same as those taking inhaled fluticasone propionate alone.
DOI: 10.13130/rd_unimi/nsvbhr/b8sdgm
title: Giugno_1890_Pagina_061.jpg

description: Bulletin of 1890/06/16
DOI: 10.13130/rd_unimi/rjrjox/y6zgee
title: Luglio_1895_Pagina_081.jpg

description: Bulletin of 1895/07/21
DOI: 10.13130/rd_unimi/xu1sm0/lne6tx
title: Giugno_1893_Pagina_036.jpg

description: Bulletin of 1893/06/09
DOI: 10.25934/pr00012282
title: A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally Advanced RCC Following Nephrectomy

description: This randomized Phase III study is to evaluate whether pazopanib compared with placebo can prevent or delay recurrence of kidney cancer in patients with moderately high or high risk of developing recurrence after undergoing kidney cancer surgery.
DOI: 10.5281/zenodo.17913898
title: Dataset and R scripts for evo3D manuscript use cases

description: Use case data sets and code for "evo3D: a generalised framework for structure-informed evolutionary analysis, implemented in R". evo3D links protein structure to multiple sequence alignment (MSA) data, generates spatial windows, and extracts the corresponding MSA subsets for use with downstream genetic statistics. The datasets here cover Hepatitis C virus E1/E2 structure and MSAs as well as analysis scripts to generate figures. With additional datasets and analysis scripts for Chikungunya virus E1/E2. The full package is available at github.com/bbroyle/evo3D.Contact: Brad Broyles (bbroyle@purdue.edu)Reference: Bradley K. Broyles, Qixin He. evo3D: a generalised framework for structure-informed evolutionary analysis, implemented in R. bioRxiv 2025.12.12.694041; doi: https://doi.org/10.64898/2025.12.12.694041
DOI: 10.5281/zenodo.17913899
title: Dataset and R scripts for evo3D manuscript use cases

description: Use case data sets and code for "evo3D: a generalised framework for structure-informed evolutionary analysis, implemented in R". evo3D links protein structure to multiple sequence alignment (MSA) data, generates spatial windows, and extracts the corresponding MSA subsets for use with downstream genetic statistics. The datasets here cover Hepatitis C virus E1/E2 structure and MSAs as well as analysis scripts to generate figures. With additional datasets and analysis scripts for Chikungunya virus E1/E2. The full package is available at github.com/bbroyle/evo3D.Contact: Brad Broyles (bbroyle@purdue.edu)Reference: Bradley K. Broyles, Qixin He. evo3D: a generalised framework for structure-informed evolutionary analysis, implemented in R. bioRxiv 2025.12.12.694041; doi: https://doi.org/10.64898/2025.12.12.694041
DOI: 10.13130/rd_unimi/awv4gb/vo4ahz
title: Giugno_1896_Pagina_014.jpg

description: Bulletin of 1896/06/04
DOI: 10.13130/rd_unimi/jvs9pt/deratc
title: Giugno_1892_Pagina_035.jpg

description: Bulletin of 1892/06/09
DOI: 10.13130/rd_unimi/6np0bt/ix33ux
title: Giugno_1894_Pagina_020.jpg

description: Bulletin of 1894/06/05
DOI: 10.13130/rd_unimi/cbrkhv/lp59yu
title: Gennaio_1927_Pagina_051.jpg

description: Bulletin of 1927/01/13
DOI: 10.13130/rd_unimi/v8alup/darwtj
title: Giugno_1891_Pagina_058.jpg

description: Bulletin of 1891/06/15
DOI: 10.25574/03187
title: Chandra X-ray Observatory ObsId 03187

description: OLEGS OR FOSSIL GROUPS -- STUDYING EVOLVED GALAXY SYSTEMS
DOI: 10.25934/pr00012284
title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the 16 Week Efficacy and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis

description: This study will assess the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.
DOI: 10.13130/rd_unimi/gsbgp1/v6ekkv
title: Giugno_1889_Pagina_077.jpg

description: Bulletin of 1889/06/20
DOI: 10.13130/rd_unimi/rjrjox/xijdfe
title: Luglio_1895_Pagina_092.jpg

description: Bulletin of 1895/07/23
DOI: 10.13130/rd_unimi/xu1sm0/ehwawn
title: Giugno_1893_Pagina_037.jpg

description: Bulletin of 1893/06/10
DOI: 10.25934/pr00012285
title: A Single Arm, Phase II, Open-Label Study to Determine the Efficacy of 100mg Twice Daily Oral Dosing of Midostaurin Administered to Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia +/- an Associated Hematological Clonal Non-Mast Cell Lineage Disease

description: The purpose of this study was to determine the efficacy and safety of twice daily (bid) oral midostaurin in patients with Aggressive Systemic Mastocytosis (ASM) or Mast Cell Leukemia (MCL) with or without an Associated Hematological clonal Non-Mast cell lineage Disease (AHNMD).
DOI: 10.13130/rd_unimi/awv4gb/mitzkc
title: Giugno_1896_Pagina_015.jpg

description: Bulletin of 1896/06/04
DOI: 10.13130/rd_unimi/nsvbhr/lgushl
title: Giugno_1890_Pagina_062.jpg

description: Bulletin of 1890/06/16
DOI: 10.25934/pr00012286
title: A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination With Trastuzumab and Paclitaxel, as First Line Therapy in Women With HER2 Positive Locally Advanced or Metastatic Breast Cancer

description: The purpose of this Phase III study was to confirm the value of adding everolimus to weekly paclitaxel and trastuzumab as treatment of HER2-overexpressing metastatic breast cancer.
DOI: 10.13130/rd_unimi/cbrkhv/seece8
title: Gennaio_1927_Pagina_052.jpg

description: Bulletin of 1927/01/13
DOI: 10.13130/rd_unimi/jvs9pt/8k0wn7
title: Giugno_1892_Pagina_036.jpg

description: Bulletin of 1892/06/09
DOI: 10.13130/rd_unimi/v8alup/jchvur
title: Giugno_1891_Pagina_059.jpg

description: Bulletin of 1891/06/15
DOI: 10.25574/03188
title: Chandra X-ray Observatory ObsId 03188

description: OLEGS OR FOSSIL GROUPS -- STUDYING EVOLVED GALAXY SYSTEMS
DOI: 10.25934/pr00012287
title: A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.

description: This phase III, double-blind, placebo-controlled multinational study will assess the combination everolimus, vinorelbine, and trastuzumab compared to the combination vinorelbine and trastuzumab with respect to progressive-free survival and over survival in HER2/neu positive women with locally advanced or metastatic breast cancer who are resistant to trastuzumab and have been pre-treated with a taxane.
DOI: 10.13130/rd_unimi/6np0bt/d9rdap
title: Giugno_1894_Pagina_021.jpg

description: Bulletin of 1894/06/06
DOI: 10.13130/rd_unimi/gsbgp1/douwwc
title: Giugno_1889_Pagina_078.jpg

description: Bulletin of 1889/06/20
DOI: 10.13130/rd_unimi/rjrjox/wcwtyn
title: Luglio_1895_Pagina_094.jpg

description: Bulletin of 1895/07/24
DOI: 10.13130/rd_unimi/xu1sm0/isictn
title: Giugno_1893_Pagina_038.jpg

description: Bulletin of 1893/06/10